Cases and Conversations™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing CV Events and Patient Hospitalizations With COVID-19 Considerations

Release Date: May 24, 2021
Expiration Date: May 24, 2022

Activity Overview

Although impaired glucose metabolism has a central role in the pathology of cardiovascular (CV) complications in people with type 2 diabetes (T2D), several studies have demonstrated that CV risk cannot necessarily be reduced by achieving a normal serum glucose goal. Recent trials have provided valuable insights concerning the cardiovascular benefits of some antidiabetes medications, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists. In fact, the American Diabetes Association (ADA) now recommends that, in addition to metformin, patients with T2D and established (ASCVD) should receive a glucose-lowering drug shown to reduce major CV events.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Cases & Conversations™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing CV Events and Patient Hospitalizations with COVID-19 Considerations held in April 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with T2D and cardiovascular disease, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Target Audience

This educational program is directed toward primary care physicians, diabetologists, endocrinologists, cardiologists, certified diabetes educators, nurse practitioners, and physician assistants; other health care providers who treat patients with T2DM will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Examine current treatment guidelines for patients with T2D for effective management of cardiovascular risk
• Evaluate the real-world evidence for reducing cardiovascular events and hospitalizations to improve outcomes for patients with T2D
• Apply emerging clinical data on issues in management of T2D in patients with COVID-19 toward the development of treatment plans

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Chair

Harold Edward Bays, MD, FOMA, FTOS, FACC, FNLA, FASPC
Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center
Your Body Goal
Louisville, KY

Disclosures: Grant/Research Support: 89Bio, Acasti Pharma, Akcea Therapeutics, Allergan, Alon MedTech/Epitome Pharmaceuticals, Amarin Corp, Amgen, AstraZeneca, Axsome Therapeutics, Biohaven Pharmaceuticals, Bionime, Boehringer Ingelheim, CiVi Biopharma, Eli Lilly and Co, Esperion Therapeutics, Evidera, Gan & Lee Pharmaceuticals, Home Access, Janssen Pharmaceuticals, Johnson & Johnson, Lexicon Pharmaceuticals, Matinas BioPharma, Merck & Co, Metavant Sciences, Novartis Pharmaceuticals, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Selecta Biosciences, Timi Pharmaceuticals, Urovant Sciences; Consultant: 89Bio, Amarin Corp, Esperion Therapeutics, Gelesis, Matinas BioPharma; speaker for Esperion Therapeutics, Novo Nordisk.

Faculty

Ann Marie Navar, MD, PhD, FAHA, FACC, FASPC
Associate Professor of Medicine (Cardiology)
UT Southwestern Medical School
Dallas, TX

Disclosures: Grant/Research Support: Amarin Corp, Amgen, Bristol Myers Squibb, Janssen Pharmaceuticals, Regeneron, Sanofi; Consultant: Amarin Corp, Amgen, AstraZeneca, Boehringer Ingelheim, Esperion, Janssen Pharmaceuticals, Eli Lilly and Co, The Medicines Company, Novartis Pharmaceuticals Corp, Novo Nordisk, Regeneron, Sanofi.

Lucia M. Novak, MSN, ANP-BC, BC-ADM
Nurse Practitioner
Board-Certified, Adult Health and Advanced Diabetes Management
President and Owner
Diabetes Consulting Services
North Bethesda, MD
Co-Executive Director
Capital Health & Metabolic Center
Capital Diabetes & Endocrine Associates
Camp Springs/Silver Spring, MD

Disclosures: Consultant: Abbott Diabetes Care, Novo Nordisk, Xeris Pharmaceuticals; Speakers’ Bureau: Abbott Diabetes Care, AstraZeneca, Novo Nordisk, Xeris Pharmaceuticals.

Peter P. Toth, MD, PhD, FCCP, FASPC, FAHA, FESC, FACC
President, American Society for Preventive Cardiology
Director, Preventive Cardiology
CGH Medical Center
Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI
Adjunct Associate Professor Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosures: Consultant: Amarin Corp, Kowa Pharmaceuticals America, Resverlogix Corp, Theravance Biopharma; Speakers’ Bureau: Amarin Corp, Esperion Therapeutics, Novo Nordisk.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.